Tata Chemicals Limited — Quarter ended 31 March, 2026 (and year ended 31 March, 2026)
The following tables are extracted from the provided quarterly results document (₹ in crore).
| Particulars | Quarter ended 31 March, 2026 (Audited) (note 5) | Quarter ended 31 December, 2025 (Unaudited) | Quarter ended 31 March, 2025 (Audited) (note 5) | Year ended 31 March, 2026 (Audited) | Year ended 31 March, 2025 (Audited) |
|---|---|---|---|---|---|
| 1 Income | |||||
| a) Revenue from operations | 3,438 | 3,550 | 3,509 | 14,584 | 14,887 |
| b) Other income | 44 | 38 | 42 | 316 | 225 |
| Total income (1a + 1b) | 3,482 | 3,588 | 3,551 | 14,900 | 15,112 |
| 2 Expenses | |||||
| a) Cost of materials consumed | 688 | 710 | 580 | 2,958 | 2,560 |
| b) Purchases of stock-in-trade | 56 | 33 | 84 | 305 | 290 |
| c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (73) | 69 | 45 | (79) | 28 |
| d) Employee benefits expense | 524 | 505 | 484 | 2,060 | 1,989 |
| e) Power and fuel | 460 | 444 | 593 | 1,799 | 2,421 |
| f) Freight and forwarding charges | 768 | 767 | 735 | 2,955 | 2,736 |
| g) Finance costs | 153 | 146 | 137 | 590 | 563 |
| h) Depreciation and amortisation expense | 343 | 293 | 293 | 1,201 | 1,123 |
| i) Other expenses | 741 | 677 | 661 | 2,781 | 2,910 |
| Total expenses (2a to 2i) | 3,660 | 3,644 | 3,612 | 14,570 | 14,620 |
| 3 (Loss)/profit before exceptional items, share of profit of joint ventures and associate and tax (1-2) | (178) | (56) | (61) | 330 | 492 |
| 4 Exceptional items (net) (note 2) | (1,837) | (54) | (55) | (1,956) | (125) |
| 5 (Loss)/profit before share of profit of joint ventures and associate and tax (3+4) | (2,015) | (110) | (116) | (1,626) | 367 |
| 6 Share of profit of joint ventures and associate (net of tax) | 33 | 37 | 24 | 167 | 154 |
| 7 (Loss)/profit before tax (5+6) | (1,982) | (73) | (92) | (1,459) | 521 |
| 8 Tax expenses | |||||
| a) Current tax (note 3(a)) | 19 | 20 | (34) | 172 | 126 |
| b) Deferred tax | 115 | (24) | 9 | 84 | 41 |
| Total tax expenses (8a + 8b) | 134 | (4) | (25) | 256 | 167 |
| 9 (Loss)/profit from continuing operations after tax (7-8) | (2,116) | (69) | (67) | (1,715) | 354 |
| 10 Exceptional gain from discontinued operations (note 4) | – | – | 27 | – | 47 |
| 11 Tax expenses of discontinued operations | – | – | 9 | – | 14 |
| 12 Profit from discontinued operations after tax (10-11) | – | – | 18 | – | 33 |
| 13 (Loss)/profit for the period (9+12) | (2,116) | (69) | (49) | (1,715) | 387 |
| 14 Other comprehensive income (“OCI”) – gain/(loss) | |||||
| a) (i) Items that will not be reclassified to the Consolidated Statement of Profit and Loss | |||||
| – Change in fair value of equity investments carried at fair value through OCI | (536) | 877 | (137) | 853 | (621) |
| – Remeasurement of defined employee benefit plans | 194 | (5) | 162 | 173 | 169 |
| (ii) Income Tax relating to above items – charge (note 3(b)) | (45) | 84 | – | 109 | 80 |
| (iii) Share of other comprehensive credit /(charge) of joint ventures (net of tax) | (66) | 69 | (49) | 10 | (216) |
| b) (i) Items that will be reclassified to the Consolidated Statement of Profit and Loss | |||||
| – Effective portion of cash flow hedges | 65 | (12) | 33 | 31 | 65 |
| – Changes in foreign currency translation reserve | 416 | 105 | (34) | 818 | 191 |
| (ii) Income Tax relating to above items – charge | (2) | (2) | 5 | (5) | 11 |
| (iii) Share of other comprehensive (charge) / credit of joint ventures (net of tax) | 6 | 1 | – | 9 | 2 |
| Total other comprehensive income (net of tax) (a(i-ii+iii)+b(i-ii+iii)) | 123 | 953 | (30) | 1,790 | (501) |
| 15 Total comprehensive income for the period (13+14) | (1,993) | 884 | (79) | 75 | (114) |
| 16 (Loss)/profit from continuing operations after tax (9) | |||||
| Attributable to: Equity shareholders of the Company | (2,132) | (93) | (74) | (1,896) | 202 |
| Attributable to: Non-controlling interests | 16 | 24 | 7 | 181 | 152 |
| (Loss)/profit from continuing operations after tax (9) | (2,116) | (69) | (67) | (1,715) | 354 |
| 17 Profit from discontinued operations after tax (12) | |||||
| Attributable to: Equity shareholders of the Company | – | – | 18 | – | 33 |
| Attributable to: Non-controlling interests | – | – | – | – | – |
| Profit from discontinued operations after tax (12) | – | – | 18 | – | 33 |
| 18 (Loss)/profit for the period (13) | |||||
| Attributable to: Equity shareholders of the Company | (2,132) | (93) | (56) | (1,896) | 235 |
| Particulars | Quarter ended 31 March, 2026 (Audited) (note 5) | Quarter ended 31 December, 2025 (Unaudited) | Quarter ended 31 March, 2025 (Audited) (note 5) | Year ended 31 March, 2026 (Audited) | Year ended 31 March, 2025 (Audited) |
|---|---|---|---|---|---|
| 1 Segment Results (Profit before share of profit of joint ventures and tax) | – | – | 27 | – | 47 |
| Particulars | Quarter ended 31 March, 2026 (Audited) (note 5) | Quarter ended 31 December, 2025 (Unaudited) | Quarter ended 31 March, 2025 (Audited) (note 5) | Year ended 31 March, 2026 (Audited) | Year ended 31 March, 2025 (Audited) |
|---|---|---|---|---|---|
| 1 Segment Revenue | |||||
| a. Basic chemistry products | 2,933 | 2,887 | 3,037 | 11,521 | 12,080 |
| b. Specialty products | 505 | 667 | 472 | 3,076 | 2,815 |
| 3,438 | 3,554 | 3,509 | 14,597 | 14,895 | |
| Less: Inter segment revenue | – | 4 | 1 | 13 | 9 |
| 3,438 | 3,550 | 3,508 | 14,584 | 14,886 | |
| Add: Unallocated | – | – | 1 | – | 1 |
| Total revenue from operations | 3,438 | 3,550 | 3,509 | 14,584 | 14,887 |
| 2 Segment Results | |||||
| a. Basic chemistry products (note 2(a and c)) | (1,802) | 71 | 84 | (1,311) | 778 |
| b. Specialty products | (46) | (21) | (63) | 168 | 120 |
| Total segment results | (1,848) | 50 | 21 | (1,143) | 898 |
| Less: (i) Finance costs | 153 | 146 | 137 | 590 | 563 |
| Less: (ii) Net unallocated expense/(income) | 14 | 14 | – | (107) | (32) |
| Profit before share of profit of joint ventures and associate and tax | (2,015) | (110) | (116) | (1,626) | 367 |
| 3 Segment Assets | |||||
| a. Basic chemistry products | 24,004 | 24,600 | 23,472 | 24,004 | 23,472 |
| b. Specialty products | 3,374 | 3,290 | 3,102 | 3,374 | 3,102 |
| Total segment assets | 27,378 | 27,890 | 26,574 | 27,378 | 26,574 |
| Add: Unallocated | 11,653 | 12,281 | 11,206 | 11,653 | 11,206 |
| Total assets | 39,031 | 40,171 | 37,780 | 39,031 | 37,780 |
| 4 Segment Liabilities | |||||
| a. Basic chemistry products | 4,259 | 4,190 | 4,318 | 4,259 | 4,318 |
| b. Specialty products | 1,252 | 1,056 | 1,032 | 1,252 | 1,032 |
| Total segment liabilities | 5,511 | 5,246 | 5,350 | 5,511 | 5,350 |
| Add: Unallocated | 11,345 | 10,735 | 9,929 | 11,345 | 9,929 |
| Total liabilities | 16,856 | 15,981 | 15,279 | 16,856 | 15,279 |
| Particulars | Quarter ended 31 March, 2026 (Audited) (note 5) | Quarter ended 31 December, 2025 (Unaudited) | Quarter ended 31 March, 2025 (Audited) (note 5) | Year ended 31 March, 2026 (Audited) | Year ended 31 March, 2025 (Audited) |
|---|---|---|---|---|---|
| 1 Segment Results (Profit before share of profit of joint ventures and tax) | – | – | 27 | – | 47 |
| Particulars | As at 31 March, 2026 (Audited) | As at 31 March, 2025 (Audited) |
|---|---|---|
| I. ASSETS | ||
| (1) Non-current assets | ||
| (a) Property, plant and equipment | 9,920 | 8,073 |
| (b) Capital work-in-progress | 1,014 | 1,879 |
| (c) Investment Property | 30 | 50 |
| (d) Right of use assets | 813 | 721 |
| (e) Goodwill | 515 | 2,245 |
| (f) Other intangible assets | 9,324 | 8,511 |
| (g) Intangible assets under development | 24 | 34 |
| (h) Financial assets | ||
| (i) Investments accounted for using the equity method | 1,460 | 1,327 |
| (ii) Other investments | 7,715 | 7,012 |
| (iii) Other financial assets | 38 | 27 |
| (i) Deferred tax assets (net) | 33 | 30 |
| (j) Non-current tax assets (net) | 767 | 930 |
| (k) Other non-current assets | 172 | 221 |
| Total non-current assets | 31,825 | 31,060 |
| (2) Current assets | ||
| (a) Inventories | 3,082 | 2,558 |
| (b) Financial assets | ||
| (i) Investments | 711 | 805 |
| (ii) Trade receivables | 2,088 | 1,900 |
| (iii) Cash and cash equivalents | 381 | 548 |
| (iv) Bank balances other than (iii) above | 61 | 67 |
| (v) Other financial assets | 160 | 146 |
| (c) Current tax assets (net) | 10 | 37 |
| (d) Other current assets | 710 | 659 |
| Assets classified as held for sale | 3 | – |
| Total current assets | 7,206 | 6,720 |
| Total assets | 39,031 | 37,780 |
| II. EQUITY AND LIABILITIES | ||
| (1) Equity | ||
| (a) Equity share capital | 255 | 255 |
| (b) Other equity | 20,951 | 21,339 |
| Equity attributable to equity share holders | 21,206 | 21,594 |
| Non-controlling interests | 969 | 907 |
| Total equity | 22,175 | 22,501 |
| (2) Liabilities | ||
| 1 Non-current liabilities | ||
| (a) Financial liabilities | ||
| (i) Borrowings | 4,663 | 4,166 |
| (ii) Lease liabilities | 714 | 650 |
| (iii) Other financial liabilities | 2 | 26 |
| (b) Provisions | 1,382 | 1,363 |
| (c) Deferred tax liabilities (net) | 2,930 | 2,541 |
| (d) Other non-current liabilities | 422 | 394 |
| Total non-current liabilities | 10,113 | 9,140 |
| 2 Current liabilities | ||
| (a) Financial liabilities | ||
| (i) Borrowings | 2,451 | 2,138 |
| (ii) Lease liabilities | 173 | 118 |
| (iii) Trade payables | ||
| – Outstanding dues of micro enterprises and small enterprises | 25 | 15 |
| – Outstanding dues of creditors other than above | 2,527 | 2,495 |
| (iv) Other financial liabilities | 683 | 545 |
| (b) Other current liabilities | 544 | 527 |
| (c) Provisions | 327 | 292 |
| (d) Current tax liabilities (net) | 13 | 9 |
| Total current liabilities | 6,743 | 6,139 |
| Total liabilities | 16,856 | 15,279 |
| Total equity and liabilities | 39,031 | 37,780 |
| Description | Year ended 31 March, 2026 (Audited) | Year ended 31 March, 2025 (Audited) |
|---|---|---|
| A Cash flows from operating activities | ||
| (Loss)/profit before tax from continuing operations | (1,459) | 521 |
| Profit before tax from discontinued operations | – | 47 |
| (Loss)/profit before tax (total) | (1,459) | 568 |
| Adjustments for: | ||
| Depreciation and amortisation expense | 1,201 | 1,123 |
| Impairment of Goodwill (note 2(b)) | 1,837 | – |
| Impairment of Intangible assets under development | – | 7 |
| Finance costs | 590 | 563 |
| Interest income | (73) | (45) |
| Dividend income | (99) | (68) |
| Share of profit of joint ventures and associate | (167) | (154) |
| Net gain on sale of current investments | (52) | (51) |
| Provision for employee benefits expense | 114 |